THALES
5.8.2021 04:02:05 CEST | Business Wire | Press release
Thales and Dah Chong Hong – Dragonair Airport GSE Service Ltd. (DAS) announced that they have been selected by the Civil Aviation Department (CAD) of the Hong Kong Special Administrative Region Government through global open tender exercise to deploy the new Instrument Landing System (ILS) and to support the Three-runway System (3RS) expansion project at the Hong Kong International Airport (HKIA). This leading solution will largely help HKIA further improve the capacity and efficiency of aircraft landing while maintaining the highest standard of flight safety.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005024/en/
The six sets of new ILS to be installed at the HKIA under 3RS will make use of Thales state-of-the-art technologies. The new ultra-wide aperture localizer array with 32-element localizer antenna will provide highly accurate guidance signals to aircraft approaching and landing on the runway in all weather conditions, day and night, allowing the safest and the most efficient aircraft landing at the HKIA while requiring less equipment safeguarding area.
The new ILS will also support selected runways with Category III operations including Low Visibility Operations (LVO) under foggy/heavy rain conditions. The whole Thales solution has already been deployed at various major international airports, such as Istanbul New Airport and Ankara Esenboga Airport in Turkey as well as Paris Charles De Gaulle Airport in France.
In Hong Kong, Thales has been supporting HKIA with superior products and technologies over the past 20 years as it has grown and become one of the busiest regional and international aviation hub. With HKIA stepping up its capacity to cater for the increasing demand of air traffic growth, Thales, as one of the most trusted partners of CAD, will once again contribute to “one of the largest infrastructure projects in Hong Kong’s history”.
“We are proud to have been selected by the Civil Aviation Department under global open tender as the supplier of new ILS for the HKIA, which is one of the key systems with proven international reference and reliability performance to support operations on the runway. This new selection strengthens our position as a proven airspace solutions provider in Asia and makes HKIA a world reference in terms of navigation aids equipped airport. I am sure the knowledge and experience that Thales is bringing to the project will ensure smooth and reliable operations at the HKIA during aircraft landing.” Mr. Kais MNIF, Navigation and Non-radar Surveillance Global Business Director, Thales.
“We are also delighted to work together with Thales as the local partner for the ILS solution. This project will leverage the strength and expertise of both companies to jointly deliver a world-class critical air navigation service equipment to CAD at the Hong Kong International Airport.” Angel Cheung, General Manager, Dah Chong Hong – Dragonair Airport GSE Service Ltd.
DAS is responsible for the project liaison and coordination with various stakeholders, overall logistic support, and on-site installation of this advanced ILS project. Thales together with DAS, commit to ensuring on-time and satisfying delivery of the solution to the CAD. Both companies have cooperated on several aviation projects to cater for future aviation traffic growth in the region, which will definitely further accelerate the on-going development in the Guangdong-Hong Kong-Macau Greater Bay Area.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
About Thales in China
Thales provides innovative solutions for the infrastructure that forms the backbone of China’s growth. The Group has been present in China for more than 40 years and is the trusted partner for the Chinese aviation and urban rail transportation industries. In the meanwhile, from secure software to biometrics and encryption, Thales has successfully applied its advanced technology to mobile communication, banking, IoT and software monetization etc. Thales has 3 JVs and employs 2,100 people with offices located in 7 cities in China. Thales established R&D centers and Innovation Hubs in Beijing, Dalian and Hong Kong to provide innovative solutions for both China and international market.
About Dah Chong Hong – Dragonair Airport GSE Service Ltd.
Dah Chong Hong –Dragonair Airport GSE Service Ltd. (“DAS”), a subsidary of Dah Chong Hong Holdings established in 1996, is an aviation support service provider with operations in Hong Kong and mainland China. DAS provides a wide array of professional services for the global aviation industry including supply, development and implementation of airport special system as well as design, supply, maintenance, leasing and fleet management of aviation and airport ground support equipment.
About Dah Chong Hong Holdings
Dah Chong Hong Holdings, an indirect wholly owned subsidiary of CITIC Limited (stock code: 0267.HK), is an integrated trading and distribution company operating in Asia, supported by an extensive logistics network. DCH is a leading distributor and dealer of motor vehicles in Greater China as well as a provider of a full range of associated services. DCH’s consumer business comprises the manufacture, retail and distribution of food, healthcare, electrical appliances, beauty and lifestyle products. DCH employs over 16,500 staff with operations in 12 Asian markets.
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom